Crossmark

A quadruple blinded placebo controlled randomised trial to evaluate the effectiveness of an Iodine complex for patients with mild to moderate COVID-19 in Pakistan (I-COVID-PK): A structured summary of a study protocol for a randomised controlled trial

Crossref DOI link: https://doi.org/10.1186/s13063-021-05081-3

Published Online: 2021-02-10

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ashraf, Sohaib https://orcid.org/0000-0003-3127-3557
Ashraf, Shoaib https://orcid.org/0000-0002-1218-4877
Ashraf, Moneeb https://orcid.org/0000-0002-5769-9524
Imran, Muhammad Ahmad https://orcid.org/0000-0003-3358-229X
Kalsoom, Larab https://orcid.org/0000-0003-1075-6285
Siddiqui, Uzma Nasim

Farooq, Iqra

Ghufran, Muhammad

Khokhar, Romaisa Arshad

Akram, Muhammad Kiwan https://orcid.org/0000-0002-8415-9363
Shahid, Iqra

Sohaib Ur Rehman, Muhammad

Akmal, Rutaba

Tahir, Arbaz

Zahid, Ayesha

Ashraf, Sidra https://orcid.org/0000-0002-4254-2583
Rafique, Sundas

Matti, Nazish

Nadeem, Muhammad Faisal

Humayun, Ayesha

Malik, Amber

Saboor, Qazi Abdul

Ahmad, Ali

Ashraf, Muhammad

Izhar, Mateen
License Information

Text and Data Mining valid from 2021-02-10

Version of Record valid from 2021-02-10
More Information

Article History

Received: 23 January 2021

Accepted: 29 January 2021

First Online: 10 February 2021

Ethics approval and consent to participate

: The study was approved by the Ethics Committee of Shaikh Zayed Hospital on July 14<sup>th</sup>, 2020. The Approval ID number of the study is SZMC/IRB/Internal0056/2020. I certify that this trial has received ethical approval from the appropriate ethical committee as described above. Prior to enrolment, participants will be fully informed of the study and asked to sign the consent form in order to be eligible for randomization and participation.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below